Selonsertib

Selonsertib

SCHEMBL30714545

CCS(=O)(=O)O.Cc1cc(F)c(C(=O)Nc2cccc(-c3nncn3C(C)C)n2)cc1-n1cnc(C2CC2)c1

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAP3K5

The experimentally established mechanism targets of Selonsertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAP3K5 known ✓ Q99683 20/20 0.90
MAP3K6 O95382 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Selonsertib SCHEMBL17873148 0.97 MAP3K5 (0.89) MAP3K5MAP3K6
Selonsertib SCHEMBL17873177 0.96 MAP3K5 (0.94) MAP3K5MAP3K6
Selonsertib SCHEMBL17873147 0.96 MAP3K5 (0.94) MAP3K5MAP3K6
Selonsertib SCHEMBL29977277 0.95 MAP3K5 (1.00) MAP3K5MAP3K6
Selonsertib SCHEMBL14672984 0.95 MAP3K5 (1.00) MAP3K5MAP3K6
Selonsertib SCHEMBL17873132 0.94 MAP3K5 (0.98) MAP3K5MAP3K6
Selonsertib SCHEMBL17873174 0.93 MAP3K5 (0.96) MAP3K5MAP3K6
Selonsertib SCHEMBL17873192 0.93 MAP3K5 (0.87) MAP3K5MAP3K6
Selonsertib SCHEMBL17873149 0.92 MAP3K5 (0.92) MAP3K5MAP3K6
Selonsertib SCHEMBL17873198 0.92 MAP3K5 (0.92) MAP3K5MAP3K6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265250-A2 SOLID FORMS OF AN ASK1 INHIBITOR Gilead Sciences, Inc. (US) 2023-10-25 EP claimed
EP-4265250-A2 SOLID FORMS OF AN ASK1 INHIBITOR Gilead Sciences, Inc. (US) 2023-10-25 EP disclosed